Osteoradionecrosis & PENTOCLO Protocol: Retrospective Study

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

osteoradionecrosis (ORN) affects up to 30% of irradiated patients and can occur up to several decades after stopping treatment. Differents therapeutics exist but there is no consensus concerning the management of the maxillary ORN. The understanding of new pathological mechanisms opens the way to new therapeutic perspectives.

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT06055257` - Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible	Phase 3
	Recruiting	`NCT03905005` - Jaw Reconstruction With Printed Titanium and Free Tissue Transfer

NCT number	NCT04097847
Study type	Observational
Source	University Hospital, Brest
Contact
Status	Completed
Phase
Start date	June 2, 2017
Completion date	April 1, 2019

Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study — OPEN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms